- Trials with a EudraCT protocol (3,190)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
3,190 result(s) found for: roche OR chugai OR genentech.
Displaying page 2 of 160.
EudraCT Number: 2019-000795-41 | Sponsor Protocol Number: GB41149 | Start Date*: 2019-12-30 | |||||||||||
Sponsor Name:Genentech Inc. | |||||||||||||
Full Title: A PHASE IIa, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF MTPS9579A IN PATIENTS WITH ASTHMA REQUIRING INHALED CORTICOSTE... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000191-41 | Sponsor Protocol Number: GC28210 | Start Date*: 2012-06-19 | |||||||||||
Sponsor Name:GENENTECH, Inc. | |||||||||||||
Full Title: A PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE SAFETY AND EFFICACY OF MPSK3169A IN PATIENTS WITH CORONARY HEART DISEASE OR HIGH RISK OF CORONARY HEART DISEASE | |||||||||||||
Medical condition: Coronary Heart Disease or High Risk of Coronary Heart Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) CZ (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002042-21 | Sponsor Protocol Number: PMT4979g | Start Date*: 2015-02-19 | |||||||||||
Sponsor Name:Genentech, Inc. | |||||||||||||
Full Title: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE TH... | |||||||||||||
Medical condition: Patients with locally advanced or metastatic solid tumors and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000597-26 | Sponsor Protocol Number: BO42161 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB VERSUS ECULIZUMAB IN PATIENTS WITH PA... | |||||||||||||
Medical condition: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) HU (Completed) CZ (Trial now transitioned) PT (Trial now transitioned) IE (Trial now transitioned) NL (Trial now transitioned) EE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003262-41 | Sponsor Protocol Number: GO28509 | Start Date*: 2013-05-16 | |||||||||||
Sponsor Name:Genentech, Inc. | |||||||||||||
Full Title: A PHASE II, RANDOMIZED STUDY OF PACLITAXEL WITH GDC-0941 VERSUS PACLITAXEL WITH PLACEBO IN PATIENTS WITH LOCALLY RECURRENT OR METASTATIC BREAST CANCER | |||||||||||||
Medical condition: Metastatic Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) AT (Completed) CZ (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003409-36 | Sponsor Protocol Number: GA27927 | Start Date*: 2011-11-14 | |||||||||||
Sponsor Name:Genentech, Inc. | |||||||||||||
Full Title: A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of rhuMAb Beta7 in Patients with Moderate to Severe Ulcerative Colitis | |||||||||||||
Medical condition: Ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) CZ (Completed) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004852-77 | Sponsor Protocol Number: GO29642 | Start Date*: 2015-05-27 | |||||||||||
Sponsor Name:Genentech, Inc | |||||||||||||
Full Title: AN OPEN-LABEL, PHASE I/IIA STUDY OF GDC-0810 IN POSTMENOPAUSAL WOMEN WITH LOCALLY ADVANCED OR METASTATIC ESTROGEN RECEPTOR POSITIVE BREAST CANCER | |||||||||||||
Medical condition: Patients with locally advanced or metastatic estrogen receptor (ER) positive breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001764-37 | Sponsor Protocol Number: GA30066 | Start Date*: 2017-11-14 | |||||||||||
Sponsor Name:Genentech, Inc. | |||||||||||||
Full Title: A PHASE II, OPEN-LABEL EXTENSION STUDY OF PATIENTS PREVIOUSLY ENROLLED IN STUDY GA30044 TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMI... | |||||||||||||
Medical condition: Systemic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003352-20 | Sponsor Protocol Number: BO40729 | Start Date*: 2019-04-12 | |||||||||||||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||||||||||||
Full Title: An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B) | |||||||||||||||||||||||||||||||||
Medical condition: Advanced Malignancies | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) DK (Completed) PL (Trial now transitioned) SK (Trial now transitioned) LV (Trial now transitioned) HU (Trial now transitioned) NO (Prematurely Ended) GR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Completed) CZ (Trial now transitioned) RO (Trial now transitioned) SI (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000280-81 | Sponsor Protocol Number: GO40290 | Start Date*: 2018-07-04 | ||||||||||||||||
Sponsor Name:Genentech, Inc | ||||||||||||||||||
Full Title: A PHASE II, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED STUDY OF MTIG7192A, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB IN CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC N... | ||||||||||||||||||
Medical condition: Locally advanced or metastatic non-small cell lung cancer (NSCLC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-003221-25 | Sponsor Protocol Number: NAC071 | Start Date*: 2008-01-24 | |||||||||||
Sponsor Name:United Lincolnshire Hospitals NHS Trust [...] | |||||||||||||
Full Title: Phase II study of the effectiveness of the addition of Capecitabine to a standard regimen containing Adriamycin, Cyclophosphamide and Docetaxel as neoadjuvant treatment in large or locally advanced... | |||||||||||||
Medical condition: Large (>/=3 cm) or locally advanced breast cancers | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000072-17 | Sponsor Protocol Number: BH30071 | Start Date*: 2016-06-30 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH... | |||||||||||||
Medical condition: Haemophilia A without factor VIII inhibitors | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) ES (Ongoing) DE (Completed) PL (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004377-84 | Sponsor Protocol Number: GO27834 | Start Date*: 2013-04-11 | ||||||||||||||||||||||||||
Sponsor Name:Genentech, Inc. | ||||||||||||||||||||||||||||
Full Title: A randomized, open-label, multicenter, phase II trial evaluating the safety and activity of pinatuzumab vedotin (DCDT2980S) in combination with rituximab or polatuzumab vedotin (DCDS4501A) in combi... | ||||||||||||||||||||||||||||
Medical condition: Follicular Non-Hodgkin’s Lymphoma (FL); Diffuse Large B-Cell Lymphoma (DLBCL) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) IT (Completed) NL (Completed) FR (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000897-80 | Sponsor Protocol Number: ABS4986g | Start Date*: 2011-08-16 | |||||||||||
Sponsor Name:Genentech, Inc. | |||||||||||||
Full Title: PHASE II RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF rhuMAb BETA7 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS | |||||||||||||
Medical condition: Ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) GB (Prematurely Ended) ES (Prematurely Ended) DE (Completed) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000498-19 | Sponsor Protocol Number: GA30067 | Start Date*: 2016-10-13 | |||||||||||
Sponsor Name:Genentech, Inc. | |||||||||||||
Full Title: A PHASE II OPEN-LABEL EXTENSION STUDY OF PATIENTS PREVIOUSLY ENROLLED IN STUDY GA29350 TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHR... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004165-58 | Sponsor Protocol Number: GO39590 | Start Date*: 2017-02-21 | |||||||||||
Sponsor Name:Genentech, Inc | |||||||||||||
Full Title: A PHASE II, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MOXR0916 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR ME... | |||||||||||||
Medical condition: Advanced or Metastatic Urothelial Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) PT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002224-40 | Sponsor Protocol Number: OAM4971g | Start Date*: 2012-05-14 | |||||||||||||||||||||
Sponsor Name:Genentech, Inc. | |||||||||||||||||||||||
Full Title: A randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination with Tarceva® (erlotinib) in Patients with Me... | |||||||||||||||||||||||
Medical condition: MET DIAGNOSTIC−POSITIVE NON−SMALL CELL LUNG CANCER (NSCLC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BE (Completed) ES (Completed) DE (Completed) HU (Completed) IE (Completed) NL (Completed) GB (Completed) IT (Completed) PL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005438-69 | Sponsor Protocol Number: GO29646 | Start Date*: 2015-07-10 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF ONARTUZUMAB IN PATIENTS WITH SOLID TUMORS ON STUDY TREATMENT PREVIOUSLY ENROLLED IN AN F. HOFFMANN-LA ROCHE- AND/OR GENENTECH-SPONSORED STUDY | |||||||||||||
Medical condition: Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) LV (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001549-13 | Sponsor Protocol Number: GB39242 | Start Date*: 2016-12-16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Genentech, Inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF MSTT1041A IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Uncontrolled Severe Asthma | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) CZ (Completed) PL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005431-41 | Sponsor Protocol Number: BN40900(SA-309JG) | Start Date*: 2017-10-16 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) as Monotherapy in Patients With Neuromyelitis Optica (NMO) and... | |||||||||||||
Medical condition: Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) RO (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
